SCHEMBL7863101

SCHEMBL7863101

CCS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 5/20 0.81
ADORA3 P0DMS8 2/20 0.81
MIF P14174 1/20 0.81
PDE4A P27815 1/20 0.81
PDE4D Q08499 1/20 0.81
PTGS2 P35354 3/20 0.44
TSHR P16473 2/20 0.41
BRD4 O60885 4/20 0.36
TRIM24 O15164 6/20 0.35
BRD1 O95696 6/20 0.35
BRPF1 P55201 6/20 0.35
KMT2A Q03164 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 2/20 0.34
HTT P42858 1/20 0.34
MLNR O43193 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iguratimod SCHEMBL29366981 0.90 PTGS1 (1.00) PTGS1ADORA3MIFPDE4APDE4D
Iguratimod SCHEMBL26326 0.90 PTGS1 (1.00) PTGS1ADORA3MIFPDE4APDE4D
Iguratimod SCHEMBL5455197 0.89 PTGS1 (0.98) PTGS1ADORA3MIFPDE4APDE4D
Iguratimod SCHEMBL29230458 0.84 PTGS1 (0.87) PTGS1ADORA3MIFPDE4APDE4D
SCHEMBL31114276 0.83 PTGS1 (0.77) PTGS1ADORA3MIFPDE4APDE4D
SCHEMBL8288071 0.83 ADORA3 (0.74) PTGS1ADORA3MIFPDE4APDE4D
SCHEMBL30753982 0.83 PTGS1 (0.77) PTGS1ADORA3MIFPDE4APDE4D
SCHEMBL8295858 0.82 ADORA3 (0.71) PTGS1ADORA3MIFPDE4APDE4D
SCHEMBL10417305 0.82 PTGS1 (0.85) PTGS1ADORA3MIFPDE4APDE4D
SCHEMBL10416928 0.80 PTGS1 (0.76) PTGS1ADORA3MIFPDE4APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9918963-B2 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor TOYAMA CHEMICAL CO., LTD. (JP) 2018-03-20 US claimed
EP-3078372-B1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO LTD (JP) 2017-09-13 EP claimed
EP-3078372-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2016-10-12 EP claimed
US-20160228406-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2016-08-11 US claimed
US-20160228404-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2016-08-11 US claimed
US-20150353519-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2015-12-10 US claimed
EP-2929880-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR Toyama Chemical Co., Ltd. (JP) 2015-10-14 EP claimed
EP-1140179-A2 USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA G.D. SEARLE & CO. (US) 2001-10-10 EP claimed
WO-2000038786-A2 USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA G.D. SEARLE & CO. (US) 2000-07-06 WO claimed
US-9918963-B2 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor TOYAMA CHEMICAL CO., LTD. (JP) 2018-03-20 US disclosed
EP-3078372-B1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO LTD (JP) 2017-09-13 EP disclosed
EP-3078372-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2016-10-12 EP disclosed
US-20160228406-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160228404-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20150353519-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR TOYAMA CHEMICAL CO., LTD. (JP) 2015-12-10 US disclosed
EP-1140179-A2 USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA G.D. SEARLE & CO. (US) 2001-10-10 EP disclosed
WO-2000038786-A2 USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA G.D. SEARLE & CO. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228404-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR MIF, ARG1, MSR1 PTGS1 846/4885ADORA3 3285/4885MIF 1/4885
US-20160228406-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR MIF, MMP12, CCL2 PTGS1 274/4885ADORA3 3064/4885MIF 1/4885
US-20150353519-A1 THERAPEUTIC AGENT FOR DISEASE BASED ON INHIBITORY EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR MIF, MSR1, ARG1 PTGS1 108/4885ADORA3 3011/4885MIF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.